. 2017 Mar 8;8(21):35425–35434. doi: 10.18632/oncotarget.16019

Table 3. Subgroup analysis results in meta-analysis.

				Heterogeneity		Quality of the evidence(GRADE)
Subgroup	No. study	WMD(95%CI)	P value	I² (%)	P	Quality of the evidence(GRADE)
Overall	20	-1.23 [-1.65, -0.81]	<0.001	93	<0.001	⨁◯◯◯^1,2 VERY LOW
BMI
<25	6	-0.79 [-1.28, -0.30]	<0.001	91	<0.001	⨁◯◯◯^1,2 VERY LOW
≥25	14	-1.48 [-2.16, -0.80]	<0.001	94	<0.001	⨁◯◯◯^1,2 VERY LOW
Duration(months)
<6	10	-0.94 [-1.41, -0.47]	<0.001	87	<0.001	⨁◯◯◯^1,2 VERY LOW
≥6	10	-1.47 [-2.16, -0.78]	<0.001	95	<0.001	⨁◯◯◯^1,2 VERY LOW
Dose(mg/day)
<2000	14	-1.21 [-1.32, -1.09]	<0.001	94	<0.001	⨁◯◯◯^1,2 VERY LOW
≥2000	6	-0.55 [-0.71, -0.40]	<0.001	86	<0.001	⨁◯◯◯^1,2 VERY LOW
HOMA-IR ratio
<0.735	4	-1.07 [-1.76, -0.38]	<0.001	93	<0.001	⨁◯◯◯^1,2 VERY LOW
0.735-0.865	4	-0.49 [-0.72, -0.25]	<0.001	7	0.360	⨁◯◯◯² VERY LOW
0.865-1.015	3	-1.06 [-1.86, -0.26]	<0.001	23	0.270	⨁◯◯◯² VERY LOW
<1.015	4	-1.32 [-1.56, -1.08]	<0.001	0	0.600	⨁◯◯◯² VERY LOW
NR	5	-1.98 [-3.59, -0.36]	0.020	98	<0.001	⨁◯◯◯^1,2 VERY LOW
T ratio
<0.714	4	-1.19 [-1.67, -0.70]	<0.001	40	0.170	⨁◯◯◯^1,2 VERY LOW
0.714-0.825	2	-1.85 [-2.09, -1.60]	<0.001	99	<0.001	⨁◯◯◯^1,2 VERY LOW
0.825-0.886	3	-1.35 [-1.58, -1.11]	<0.001	84	<0.001	⨁◯◯◯^1,2 VERY LOW
<0.886	4	-0.74 [-0.88, -0.60]	<0.001	91	<0.001	⨁◯◯◯^,2 VERY LOW
NR	7	-0.52 [-0.73, -0.31]	<0.001	87	<0.001	⨁◯◯◯^1,2 VERY LOW

Abbreviations: WMD, Weighted Mean Difference; HOMA-IR, homeostasis model assessment of insulin resistance; T ratio, Total testosterone ratio; NR, no reported.

¹Downgraded by 1 level for substantial heterogeneity (I2 statistic is greater than 40%)

²Downgraded by two levels for the limitations of the included studies and lower total sample size